Swai J, Gui M, Long M, et al. - Researchers herein described trends of immune response-proportions among end-stage renal disease patients on renal replacement therapy in the Coronavirus disease-2019 vaccination programs.

• From six online-databases, researchers identified 27 eligible studies describing humoral and cellular immune response proportions for up to 4 weeks post booster-vaccination.

• These studies involved 2,789 end-stage renal disease patients.

• Lower proportions of humoral and cellular immune responses were recorded among hemodialysis and kidney transplant patients relative to healthy controls.

• However, by the fourth week, there appeared an improvement in hemodialysis patients' response proportions, reaching near healthy-control levels.

• Improvement also occurred in kidney transplant patients' lower responses' proportions but these remained significantly lower than healthy controls throughout 4-weeks.

• For kidney transplant patients, it might be inadequate to implement the "one-size-fits-all" vaccination scheme.